Autologous transplantation for the treatment of chronic myelogenous leukemia

Hematology/Oncology Clinics of North America

Volumn 12, Issue 1, 1998, Pages 151-172

  Bhatia, R ^a   Forman, S J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ALPHA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 2;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; HEMATOPOIETIC STEM CELL; IMMUNOTHERAPY; NATURAL KILLER CELL; ONCOGENE; PRIORITY JOURNAL; REVIEW; STEM CELL; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0031933519     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70501-3     Document Type: Article

References (91)

1. Aganval R, Doren S, Hicks B, et al Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factoraeficient stroma favors benign progenitors. Blood 85: 1306, 1995
2. Bamett MJ, Eaves CJ, Phillips GL, et al Autografting with cultured marrow in chronic myelogenous leukemia: Results of a pilot study. Blood 84: 724, 1994
3. Bedi A, Griffin CA, Barber JP, et al Growth factor mediated terminal differentiation chronic myelogenous leukemia. Cancer Res 545: 535, 1994
4. Benyunes MC, Higuchi C, York A, et al: Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous marrow transplantation for malignant lymphoma: A feasibility trial. Bone Marrow Transplant 16: 283, 1995
5. Bhatia R, Verfaillie CM Inhibition of BCR-ABL expression by antisense oligonucleotides normalizes bl integrin mediated adhesion and regulation of proliferation in chronic myelogenous leukemia. Blood (10 suppl 1), 1740A, 1995
6. Bhatia R, McGlave PB T lymphocytes cultured from chronic myelogenous leukemia bone marrow suppress autologous hematopoietic progenitors. Leukemia 9: 1006, 1995
7. Bhatia R, McCarthy JB, Verfaillie CM Interferon-a restores normal negative regulation of CML progenitor proliferation by the marrow microenvironment by restoring normal bl integrin mediated proliferation inhibition. Blood 873: 883, 1996
8. Bhatia R, Verfaillie C: Inhibition of BCR/ABL kinase activity with tyrphostin AG957 restores bl integrin mediated microenvironmental regulation of hematopoietic progenitor proliferation in CML. Blood 88 (10 suppl 1): 675A, 1996
9. Bocchia M, Korontsvit T, Xu Q, et al: Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87: 3587, 1996
10. Boiron J-M, Cahn J-Y, Carlo-Stella C, et al: Autologous stem cell transplantation (ASCT) for patients with chronic myelogenous leukemia (CML) in first chronic phase (CP) not responding to alpha-interferon (IFN). Blood 88 (10 suppl 1): 126A, 1996
11. Buckner CD, Stewart P, Clift R, et al Treatment of blastic transformation of chronic granulocytic leukemia by chemotherapy, total body irradiation and infusion of cryopreserved autologous marrow. Exp Hematol6: 96, 1978
12. Calabretta B, Sims RB, Valiteri M, et al: Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligonucleotides: An in vitro study relevant to bone marrow purging. Proc Natl Acad Sci USA 882: 351, 1991
13. Carella AM, Frassoni F, Podesta M, et al: Idarubicin containing regimen and G-CSF are able to recruit a high rate of normal progenitor cells during early hematopoietic recovery in patients with CML. J Hematother 3199, 1994
14. Carella AM, Frassoni F, Negrin Rs: Autografting in chronic myelogenous leukemia: New questions. Leukemia 9: 365, 1995
15. Carlo-Stella C, Mangoni L, et al Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. Bone Marrow Transplant 14425, 1994
16. Cervantes F, Verfaillie C, McGlave PB, Miller JS: Autologous activated natural killer cells (ANK) suppress CML progenitors but spare normal hematopoiesis in long term bone marrow cultures (LTC). Blood 872: 476, 1996
17. Chalmers EA, Franklin IM, Kelsey S, et al: Mobilization of Ph negative progenitors into peripheral blood in chronic myelogenous leukemia (CML) using idarubicin and cytarabine. Blood 84 (10 suppl 1): 400A, 1994
18. Chaudhary A, Gajewski J, Liang JC, et al: Generation of Philadelphia-chromosomepositive dendritic cells from leukemic progenitors and their utilization for ex vivid expansion of anti-leukemic cytotoxic T-cells in chronic myelogenous leukemia. Blood 88 (10 suppl 1): 675A, 1996
19. Chervenick PA, Ellis LD, Pan SF, et al Human leukemic cells: In vitro growth of colonies containing the Philadelphia (Ph) chromosome. Science 174: 1134, 1971
20. Clift R, Appelbaum F, Thomas E: Bone marrow transplantation for chronic myelogenous leukemia. Blood 83: 2752, 1994
21. Coulombel L, Kalousek DK, Eaves CJ, et al: Long term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosomepositive chronic myelogenous leukemia. N Engl J Med 306: 1493, 1983
22. Cunningham I, Gee T, Dowling M, et al Results of treatment of Phl positive chronic myeloid leukemia with an intensive treatment regimen (L-5 protocol). Blood 53375, 1979
23. Daley GQ, Baltimore D: Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic leukemia-specific P210 bcr/abl protein. Proc Natl Acad Sci USA 85: 9312, 1988
24. Daley GQ, Van Etten RA, Baltimore D Induction of chronic myelogenous leukemia in mice by the p210 bcr/abl gene of the Philadelphia chromosome. Science 247: 824, 1990
25. de Fabritiis P, Amadori S, Petti MC, et al In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematological reconstitution after autologous bone marrow transplantation. Leukemia 9: 662, 1995
26. Degliantoni G, Mangoni N, Rizzoli V In vitro restoration of polyclonal hematopoiesis in a chronic myelogenous leukemia after in vitro treatment with 4-hydroperoxycyclophosamide. Blood 65: 753, 1985
27. Deisseroth AB, Zhifei Zu, Claxton D, et al: Genetic marking shows that Ph positive cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 83: 3068, 1994
28. DeKlein A, Van Kessel AG, Grosveld G, et al: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 300: 765, 1982
29. Dhingra K, Kurzrock R, Baine R, et al: Minimal residual disease in interferon-treated chronic myelogenous leukemia: Results and pitfalls of analysis based on polymerase chain reaction. Leukemia 6754, 1992
30. Druker BJ, Tamura S, Buchdunger E, et al Effects of a selective inhibitor of the abl tyrosine kmase on the growth of bcr-abl positive cells. Nature Medicine 2561, 1996
31. Durrant S, Taylor K, Moore D, et al Bone marrow transplant following intensive chemotherapy with filgrastim support and progenitor cell collection in advanced chronic myelogenous leukemia. Bone Marrow Transplant 15519, 1995
32. Eaves AC, Cashman JD, Gaboury LA, et al Unregulated proliferation of primitive chronic myelogenous leukemia progenitors in the presence of normal marrow adherent cells. Proc Natl Acad Sci USA 83: 5306, 1986
33. Eaves CJ, Cashman JD, Wolpe SD, et al Unresponsiveness of primitive chronic myelog enous leukemia cells to macrophage inflammatory protein la, an inhibitor of primitive normal cells. Proc Natl Acad Sci USA 901: 2015, 1993
34. Finney R, McDonald A, Baikie AG, et al Chronic granulocytic leukaemia with Ph' negative cells in bone marrow and a ten year remission after busulphan hypoplasia. Br J Haematol 23: 283, 1972
35. Forman SJ, Wright CL, Gaidulis L, et al: Lymphokine activated killer cell (LAK) purging of tumor cell contaminated human bone marrow: Effect on hematopoiesis and tumor cell kill. Blood 70319A, 1987
36. Gale RP, Champlin R: How does bone marrow transplantation cure leukemia? Lancet 228, 1984
37. Gewirtz AM, Luger S, Sokol D, et al: Oligodeoxynucleotide therapeutics for chronic myelogenous leukemiainterim results. Blood 88 (10 suppl 1): 270A, 1996
38. Giralt S, Champlin RE: Leukemia relapse after allogeneic marrow transplantation: A review. Blood 843: 603, 1994
39. Goldman J, Gale R, Horowitz M, et al: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with Tcell depletion. Ann Intern Med 108: 806, 1988
40. Gordon MY, Dowding CR, Riley GP, et al: Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 328: 342, 1987
41. Goto T, Nishikori M, Arlin Z, et al: Growth characteristics of leukemia and normal hematopoietic cells in Phl + chronic myelogenous leukemia in vivo and in vitro and effects of intensive treatment with the L15 protocol. Blood 59: 793, 1982
42. Haines ME, Goldman JM, Worsely AM, et al: Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: Probable prolongation of survival for some patients. Br J Haematol58: 711, 1984
43. Hehlman R, and the German CML Study Group: Randomized comparison of interferon-a with busulphan and hydroxyurea in chronic myelogenous leukemia. Blood 84: 4064, 1994
44. Higano CS, Raskind WH, Singer JW: Us e of alpha-interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood 80: 1437, 1992
45. Hogge DE, Coulombel L, Kalousek DK, et al Nonclonal hematopoietic progenitors in a G6PD heterozygote with chronic myelogenous leukemia revealed after long-term marrow culture. Am J Hematol 24:389, 1987
46. Horowitz M, Gale R, Sondel M, et al Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75: 555, 1990
47. Hoyle C, Gray R, Goldman J: Autografting for patients with CML in chronic phase: An update. Br J Haematol86: 76, 1994
48. Hoyle C, Bangs CD, Lane L, et al: Generation of Ph negative CD3 + CD56 + cytotoxic cells from patients with chronic phase (CP) CML: In vivo efficacy in SCID mice. Blood 88 (10 suppl 1): 675A, 1996
49. Kantarjian HM, OBrien S, Anderlini P, et al: Treatment of chronic myelogenous leukemia: Current status and investigational options. Blood 87: 3069, 1996
50. Kaur G, Gazit A, Levitzki A, et al Tryphostin induced growth inhibition: Correlation with effect on p210bcr/abl autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs 5: 213, 1994
51. Kirk JA, Reems JA, Roecklein BA, et al: Benign marrow progenitors are enriched in the CD34 + /HLA-DRlo population but not in the CD34 + /CD3810 population in chronic myelogenous leukemia: An analysis using interphase fluorescence in situ hybridization. Blood 86: 737, 1995
52. Korbling M, Burke P, Braine H, et al: Successful engraftment of blood derived stem cells in chronic myelogenous leukemia. Exp Hematol 9:684, 1981
53. Leemhuis T, Leibowitz D, Cox G, et al: Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myelogenous leukemia marrow. Blood 81: 801, 1993
54. Leopold LH, Shore SK, Newkirk TA, et al Multi-unit ribozyme-mediated cleavage of bcr-gbl mRNA in myeloid leukemias. Blood 852: 162, 1995
55. Lugo TG, Pendergast AM, Muller AJ, et al Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079, 1990
56. McGlave P, Bartsch G, Anasetti C, et al: Unrelated marrow transplantation for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program. Blood 81: 543, 1993
57. McGlave PB, De Fabritiis P, Deisseroth A, et al: Autologous transplants for chronic myelogenous leukemia: Results from eight transplant groups. Lancet 343: 1486, 1994
58. McGlave P, Miller J, Miller W, et al: Autologous marrow transplant therapy for CML using marrow treated ex vivo with human recombinant interferon gamma. Blood 84 (10 suppl 1): 537A, 1994
59. Nowell PC, Hungerford DA A minute chromosome in human chronic granulocytic leukemia. Science 132: 1497, 1960
60. OBrien SG, Rule S, Spencer A, et al Autografting in chronic phase CML using PBPCs mobilized by intermediate-dose chemotherapy. Bone Marrow Transplant 15: 511, 1995
61. Ohnishi K, Ohno R, Tomonaga M, et al: A randomized trial comparing interferon-cu with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 89: 906, 1995
62. Okabe M, Uehara Y, Miyagishima T, et al: Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: Abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition of Phl-positive leukemia cell growth. Blood 80: 1330, 1992
63. Ozer H, George S, Schiffer C, et al: Prolonged subcutaneous administration of recombinant alfa-2b interferon in patients with previously untreated Philadelphia-chromosome positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 82: 2975, 1993
64. Pigneux A, Devergie A, Pochitaloff M, et al: Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: A report from the Societ6 Francaise de Greffe de Moelle. Bone Marrow Transplant 15: 819, 1995
65. Reiffers J, Troutte R, Marit G, et al Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: A report of 47 cases. Br J Haematol 77: 339, 1991
66. Reiffers J, Goldman J, Meloni G, et al: Autologous stem cell transplantation in chronic myelogenous leukemia: A retrospective analysis of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 14: 407, 1994
67. Rowe J, Ryan D, Dipersio J, et al Autografting in chronic myelogenous leukemia followed by immunotherapy. Stem Cells 11 (suppl 3): 34, 1993
68. Rowley JD A new consistent chromosome abnormality in chronic myelogenous leukemia. Nature 243: 209, 1973
69. Shore SK, Nabissa PM, Reddy EP: Ribozyme-mediated cleavage of the bcr-abl oncogene transcript: In vitro cleavage of RNA and in vivo loss of p210 protein kinase activity. Oncogene 8: 3183, 1993
70. Simonsson B, Oberg G, Killander A, et al: Intensive treatment in order to minimize the Ph negative positive clone in chronic myelogenous leukemia. Stem Cells 111 (supp1 3) 73, 1993
71. Skorski T, Nieberowska-Skorska M, Barletta C, et al: Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. J Clin Invest 92: 194, 1992
72. Skorski T, Nieborowska-Skowrska M, Nicolaides NC, et al: Suppression of Philadelphia' leukemia growth in mice by bcr-abl antisense oligonucleotides. Proc Natl Acad Sci USA 91: 4504, 1994
73. Smalley RV, Vogel J, Huguley Jr CM, et al: Chronic granulocytic leukemia: Cytogenetic conversion of the bone marrow with cycle-specific chemotherapy. Blood 50: 107, 1977
74. Snyder DS, Wu Y, Wang JL, et al: Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome positive cell line. Blood 82600, 1993
75. Sureda A, Brunet S, Amill B, et al: Peripheral blood stem cell mobilization in patients with chronic myelogenous leukemia. Bone Marrow Transplant 15: S20, 1995
76. Szczylik C, Skorski T, Nicolaides NC, et al: Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 253: 562, 1991
77. Talpaz M, Kantarjian HM, Kurzrock R, et al: Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome positive patients. Ann Intern Med 114: 532, 1991
78. Talpaz M, Estrov Z, Kantarjian H, et al Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest 94: 1383, 1994
79. Talpaz M, Kantarjian H, Liang J, et al Percentage of Philadelphia chromosome (Ph)- negative and Ph positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood 85: 3257, 1995
80. The Italian Cooperative Study Group on Chronic Myelogenous Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myelogenous leukemia. N Engl J Med 330: 820, 1994
81. Tringali S, Santoro A, Scimi R, et al: High-dose cyclophosphamide for mobilization of circulating stem cells in chronic myelogenous leukemia. Eur J Haematol 531, 1994
82. Verfaillie C, Miller W, Kay N, et al Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: A benign cell population with potent cytotoxic activity. Blood 74: 793, 1989
83. Verfaillie C, Kay N, Miller W, et al: Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Blood 76: 401, 1990
84. Verfaillie C, Blakholmer K, McGlave P: Purified primitive human hematopoietic progenitors with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma. J Exp Med 179: 509, 1990
85. Verfaillie CM, Miller WJ, Boylan K, et al: Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 79: 1003, 1992
86. Verfaillie CM, McCarthy JB, McGlave PB Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia: Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest 90: 1232, 1992
87. Verfaillie CM, Bhatia R, Miller W, et al: Benign primitive progenitors can be selected on the basis of the CD34 + HLA-DR- phenotype in early chronic phase (ECP) but not advanced phase (AP) CML. Blood 87: 4770, 1996
88. Verma UN, Bagg A, Brown E, et al: Interleukin-2 activation of human bone marrow in long-term cultures: An effective strategy for purging and generation of anti-tumor cytotoxic effectors. Bone Marrow Transplant 13: 115, 1994
89. Wagner RW. Gene inhibition using antisense oligodeoxynucleotides. Nature 372: 333, 1994
90. Wright C, Margolin K, Forman S Activation of human bone marrow cytotoxic effector cells by interleukin-2 induction of a graft-versus-tumor effect. Proc ASCO 12: 314A, 1993
91. Zhao R, McIvor S, Verfaillie CM: Development of a retroviral gene transfer strategy that may improve disease free survival after autografting in CML. Blood 86 (suppl 10): 245A, 1996